A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

Inclusion Criteria:

1. Patients who provide written informed consent to participate in the study

2. Male or female patients ≥ 18 years of age

3. Oral LLT Cohort: Patients with documented ASCVD newly initiated on an oral lipidlowering treatment on top of a statin (e.g. ezetimibe, bempedoic acid,cholestyraimin)

4. Inclisiran Cohort: Patients newly initiated on Inclisiran fulfilling the restrictedreimbursement criteria or individual access requirements who are not at LDL-C goalas per their CV risk as recommended in the 2019 EAS/ESC guidelines (Mach et al., 2020). At least 60% of the documented patients must be PCSK9-inhibitor naive

5. Apheresis plus Inclisiran Cohort: Patients with Inclisiran on top of regular weeklyor bi-weekly lipoprotein apheresis (LDL-c or LP(a)).

Exclusion Criteria:

1. Oral LLT Cohort: Patients who receive a PCSK9-mAB or other PCSK9-targeted therapy

2. Inclisiran 1 Cohort: current or previous PCSK9-targeted treatment

3. Contraindication for Inclisiran according to the SmPC

4. Patients who have received Inclisiran previously

5. Patients with homozygous FH

6. Any underlying known disease, or surgical, physical, or medical condition that, inthe opinion of the investigator (or delegate) might interfere with interpretation ofthe clinical study results.

7. Simultaneous or planned participation in an interventional research study